CeLac and European consortium for a personalized medicine approach to Gastric Cancer
Gastric cancer is the third leading cause of cancer death in both sexes worldwide. It affects almost one million people and no strategy has improved the prognosis of the disease so far. It causes 783,000 deaths year and the survival rate for patients at an advanced stage is only about 12 months.
The primary aim of the LEGACy project is to improve gastric cancer (GC) outcomes by applying personalized medicine at the three levels of prevention in EU and CELAC populations participating in this project based on an “omics integrative epidemiology” conceptual model as a strategy to be extended worldwide.
The secondary aims of this project are to:
- Implement a personalized medicine strategy at the first level of prevention.
- Improve early GC detection through a personalized medicine strategy at the second level of prevention.
- Improve GC treatment approach through the stratification of patients for personalized medicine therapies.
- Analyse regional variations in respect to GC among the EU‐CELAC populations.
LEGACy is a partnership between 11 organisations from Argentina, Belgium, Chile, Germany, Mexico, The Netherlands, Paraguay, Portugal, and Spain.
INCLIVA’s activities in the project, beyond the coordination, focus on patients’ recruitment and samples collected in the 3 clinical studies associated, together with the epidemiological questionnaire’s completion and the analysis of the results. We also have a relevant role in disseminating the project and its results and doing a GC literacy to the civil society.
LEGACy has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 825832.